VERITAC-2: A global, randomized phase 3 study of ARV-471, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, vs fulvestrant in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer

Last Updated: Thursday, August 14, 2025

The ongoing phase 3 VERITAC-2 trial is comparing the efficacy and safety of ARV-471 to fulvestrant in approximately 560 patients with ER+ HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor and endocrine therapy. Progression-free survival is the primary endpoint; secondary endpoints include overall survival, antitumor activity, safety, and quality of life assessments.

Journal of Clinical Oncology

U.S. Food and Drug Administration

FDA approves gedatolisib with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally advanced or metastatic breast cancer

Breast Cancer Research Foundation

A revolution in breast cancer prevention is underway—With AI mammogram-based risk assessment starting at 35

Clinical Breast Cancer

Evaluating the efficacy of neoadjuvant endocrine therapy in HER2-low versus HER2-negative breast cancer

Frontiers in Oncology

Molecular characteristics and advances in precision therapeutics for HR-positive and HER2-low breast cancer

ESMO Open

Patient-reported outcomes and qualitative interviews in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Results from the phase III EMBER-3 trial

Cancers

Body mass index and outcomes in HR+/HER2- metastatic breast cancer treated with palbociclib: Insights from a national real-world study

Journal of Clinical Medicine

Is genetic testing of HER2-negative metastatic breast cancer patients implemented into clinical practice? A retrospective analysis

npj Breast Cancer

Imlunestrant with or without abemaciclib in advanced breast cancer: Safety analyses from the EMBER-3 trial

Breast Cancer Research

Efficacy of everolimus in patients with hormone receptor positive, HER2 negative, metastatic breast cancer pretreated with CDK4/6 inhibitors

Cancer Treatment Reviews

Risk of QTc prolongation, and major cardiovascular adverse events associated with CDK4/6 inhibitors in hormone receptor-positive HER2-negative breast cancer - A systematic review and meta-analysis

HR+ HER2- Breast Cancer Resource Center